Aurobindo Pharma, a leading pharmaceutical company, has announced the extension of negotiations between its subsidiary, CuraTeQ Biologics, and Merck Sharp & Dohme Singapore (MSD) for contract manufacturing operations. The negotiations, which involve biologicals production at TheraNym Biologics Pvt Ltd, have been extended until May 2024.

Initially, in October last year, CuraTeQ Biologics Pvt Ltd and MSD had signed a letter of intent (LoI) for contract manufacturing operations (CMO) for biologicals. The intention was to conclude the negotiations by March 31, 2024. However, as of the specified deadline, the negotiations are yet to be finalized.

In a regulatory filing, Aurobindo Pharma stated, “In this regard, we further inform you that said negotiations are yet to be concluded and the parties to the LoI have agreed to extend the timelines with the intention to conclude the said negotiations by May 31, 2024.”

As per the terms of the LoI, CuraTeQ proposed to cater to the requirements of the US-based biopharmaceutical company through its contract manufacturing subsidiary, TheraNym Biologics Pvt Ltd.

Additionally, CuraTeQ was expected to proceed with the procurement of certain long-lead equipment and commence civil works for the manufacturing facility. The facility is envisioned to accommodate large-scale bioreactors for mammalian cell culture drug substance manufacturing and will include a vial filling isolator line for commercial drug product manufacturing.

The extension of negotiations underscores the commitment of Aurobindo Pharma and its subsidiaries to ensure the successful establishment of contract manufacturing operations, facilitating the production of biologicals for the healthcare sector.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!